Home Featured Page 83

Featured

Latest

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

PT442 – Burning Questions About Burning Man: Mud, Ebola, and the...

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted...

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving...

BetterLife Pharma to Host Investors Update Call on September 18, 2023

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global...

Does Humanity’s Fate Lie in the Hands of the Fungal Kingdom?

PT441 – The American Psychedelic Practitioners Association and the Mission to...

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for...

BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of...

EDITOR PICKS

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.